trial

A Trial to Assess the Antipsychotic Efficacy of ITI-007

NCTId NCT02282761
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 450 (actual)
Sponsored by Intra-Cellular Therapies, Inc.
Primary completion 2015-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
450 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2014-11
Primary completion
2015-07
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
Lumateperone (Caplyta)

Sponsors

Intra-Cellular Therapies, Inc.Lead Sponsor

Investigators

1
Kimberly Vanover, Ph.D.Study Director

Sites

11 total
Little Rock, United StatesSpringdale, United StatesEscondido, United StatesGarden Grove, United StatesLong Beach, United StatesSan Diego, United StatesFort Lauderdale, United StatesRockville, United StatesSt Louis, United StatesMarlton, United StatesAustin, United States

Linked catalysts

1
A Trial to Assess the Antipsychotic Efficacy of ITI-007 — primary completion2015-07

Facts & assertions

4 sourced
Enrollment
450
Phase
PHASE3
Primary Completion Date
2015-07
Status
COMPLETED
relationships
The graph out of here
drug
Lumateperone (Caplyta)
drug
lead_sponsor
Intra-Cellular Therapies, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Kimberly Vanover, Ph.D.
person